Anticoagulation after primary PCI does not prevent adverse outcomes in STEMI patients

Anticoagulation after primary percutaneous coronary intervention (PCI) does not prevent adverse outcomes in patients with ST-segment elevation myocardial infarction (STEMI), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

NS Pharma asset gains FDA rare paediatric disease status

NS Pharma’s NS-089/NCNP-02 (brogidirsen) is intended for patients with Duchenne muscular dystrophy. Credit: Jose Luis Calvo via Shutterstock.com. The US Food and Drug Administration (FDA) has

July 10, 2023

Patients with chronic fatigue syndrome benefit from cognitive behavior therapy

Researchers from Amsterdam UMC and King’s College London have shown that Cognitive Behavioral Therapy (CBT) is beneficial for those with ME/CFS.

November 6, 2023

UQ and AbGenics partner to develop new drugs against antimicrobial resistance

UQ researchers have been awarded almost $1 million through the Australia-India Strategic Research Fund (AISRF) to combat the threat of antimicrobial resistance to human health.

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.